Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 56

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 56
---
 $2.0 million partially offset by payments of principal on insurance financing arrangements of $0.4 million.

For the three months ended March 31, 2024, net cash provided by financing activities was $1.2 million, which was primarily attributable to proceeds from the issuance of stock.

       34

Future Funding Requirements

We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements for at least the next twelve months and the foreseeable future.

We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of a failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.

Potential near-term sources of additional funding include:

     ●
     any royalties or net sales milestone payments generated under the AZSTARYS License Agreement;

     ●
     any reimbursements received for arimoclomol under the French AC;

     ●
     any product sales of OLPRUVA; and

     ●
     any product sales of MIPLYFFA.

We cannot guarantee that we will be able to generate sufficient proceeds from any of these potential sources to fund our operating expenses. We anticipate that our expenses will fluctuate substantially as we:

      ● 
      continue our ongoing clinical trials and our product development activities for our pipeline of product candidates; 

      ● 
      seek regulatory approvals for any product candidates that successfully complete clinical trials; 

     ●
     continue research and development and clinical trials of our product candidates;

      ● 
      seek to discover and develop additional product candidates either internally or in partnership with other pharmaceutical companies; 

     ●
     adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;

     ●
     maintain, expand and protect our intellectual property portfolio; and

     ●
     incur additional legal, accounting and other expenses in operating as a public company.

To date, we have generated revenue from product sales of MIPLYFFA and OLPRUVA, reimbursements